Susquehanna International Group’s Cellectis CLLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $209K | Buy |
65,942
+13,519
| +26% | +$51.8K | ﹤0.01% | 11615 |
|
|
2025
Q4 | $254K | Sell |
52,423
-1,442
| -3% | -$6.03K | ﹤0.01% | 10337 |
|
|
2025
Q3 | $154K | Buy |
53,865
+19,432
| +56% | +$50.3K | ﹤0.01% | 11259 |
|
|
2025
Q2 | $52K | Buy |
+34,433
| New | +$49.8K | ﹤0.01% | 12101 |
|
|
2024
Q4 | – | Sell |
-13,010
| Closed | -$27.8K | – | 12290 |
|
|
2024
Q3 | $27.8K | Buy |
+13,010
| New | +$28.3K | ﹤0.01% | 11554 |
|
|
2024
Q2 | – | Sell |
-27,655
| Closed | -$72.5K | – | 12141 |
|
|
2024
Q1 | $73.3K | Buy |
27,655
+8,131
| +42% | +$22.5K | ﹤0.01% | 11381 |
|
|
2023
Q4 | $60.1K | Buy |
+19,524
| New | +$46.3K | ﹤0.01% | 11640 |
|
|
2023
Q1 | – | Sell |
-58,087
| Closed | -$122K | – | 12646 |
|
|
2022
Q4 | $122K | Buy |
+58,087
| New | +$132K | ﹤0.01% | 10746 |
|
|
2022
Q1 | – | Sell |
-22,287
| Closed | -$123K | – | 13065 |
|
|
2021
Q4 | $181K | Buy |
22,287
+11,170
| +100% | +$110K | ﹤0.01% | 11566 |
|
|
2021
Q3 | $140K | Sell |
11,117
-11,559
| -51% | -$160K | ﹤0.01% | 11839 |
|
|
2021
Q2 | $351K | Sell |
22,676
-17,597
| -44% | -$296K | ﹤0.01% | 10426 |
|
|
2021
Q1 | $814K | Sell |
40,273
-5,348
| -12% | -$132K | ﹤0.01% | 8264 |
|
|
2020
Q4 | $1.23M | Buy |
+45,621
| New | +$1.02M | ﹤0.01% | 6207 |
|
|
2020
Q1 | – | Sell |
-26,356
| Closed | -$393K | – | 10278 |
|
|
2019
Q4 | $451K | Buy |
+26,356
| New | +$352K | ﹤0.01% | 7188 |
|
|
2019
Q3 | – | Sell |
-14,411
| Closed | -$225K | – | 10208 |
|
|
2019
Q2 | $225K | Buy |
14,411
+462
| +3% | +$8.25K | ﹤0.01% | 8897 |
|
|
2019
Q1 | $256K | Buy |
+13,949
| New | +$247K | ﹤0.01% | 7489 |
|
|
2018
Q4 | – | Sell |
-23,182
| Closed | -$537K | – | 9021 |
|
|
2018
Q3 | $654K | Sell |
23,182
-9,607
| -29% | -$276K | ﹤0.01% | 6049 |
|
|
2018
Q2 | $928K | Buy |
32,789
+4,002
| +14% | +$119K | ﹤0.01% | 5514 |
|
|
2018
Q1 | $907K | Sell |
28,787
-60
| -0.2% | -$1.9K | ﹤0.01% | 5457 |
|
|
2017
Q4 | $841K | Buy |
28,847
+6,262
| +28% | +$171K | ﹤0.01% | 5586 |
|
|
2017
Q3 | $643K | Sell |
22,585
-7,149
| -24% | -$185K | ﹤0.01% | 6080 |
|
|
2017
Q2 | $768K | Buy |
29,734
+257
| +0.9% | +$6.13K | ﹤0.01% | 5817 |
|
|
2017
Q1 | $707K | Buy |
29,477
+14,282
| +94% | +$300K | ﹤0.01% | 5848 |
|
|
2016
Q4 | $258K | Buy |
15,195
+3,528
| +30% | +$65.2K | ﹤0.01% | 8236 |
|
|
2016
Q3 | $281K | Buy |
+11,667
| New | +$305K | ﹤0.01% | 7036 |
|
Other funds holding CLLS
BGI
LFCM
NAMI
Susquehanna International Group's CLLS Position: Q1 2026 in Review
Susquehanna International Group increased its Cellectis (CLLS) stake by 26% in Q1 2026, buying an estimated $51.8K and bringing the position to 65,942 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #11615.
Susquehanna International Group first reported a position in CLLS in Q3 2016 and has held it in 25 quarters since. The position peaked at $1.23M in Q4 2020. 32 funds tracked by Wall St. Rank hold CLLS as of Q1 2026.
- Susquehanna International Group held 65,942 shares of Cellectis worth $209K as of Q1 2026.
- Susquehanna International Group bought 13,519 Cellectis shares in Q1 2026, an estimated $51.8K.
- Cellectis made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11615 holding.
- Susquehanna International Group first reported a position in Cellectis in Q3 2016 and has held it in 25 quarters since.
- Susquehanna International Group's Cellectis position peaked at $1.23M in Q4 2020.
- 32 funds tracked by Wall St. Rank held Cellectis as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.